CAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will implement a 1-for-25 reverse stock split of the issued shares of the company’s common stock (the Reverse Stock Split), effective at 5:00 p.m. Eastern Time on July 25, 2025. The Reverse Stock Split was approved by the company’s s ...